Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

Overview

A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepithelial lesions (HSIL).

Full Title of Study: “A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2021

Detailed Description

To evaluate the efficacy and safety of Cevira® compared to placebo in treatment of patients with cervical histologic HSIL.A total of 384 subjects will be enrolled globally, among which, 300 subjects of them will be enrolled in China.

Interventions

  • Combination Product: Cevira®
    • The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
  • Combination Product: Placebo
    • The placebo device is identical in appearance as the Cevira® device, but does not provide light.

Arms, Groups and Cohorts

  • Experimental: Cevira® treatment
    • The Cevira® treatment is an integrated combination of drug and device
  • Placebo Comparator: Placebo ointment
    • The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.

Clinical Trial Outcome Measures

Primary Measures

  • The proportion of responders at 6 months after first treatment
    • Time Frame: 6 months
    • A responder is defined as follows: Normal histology; or LSIL histology and clearance of baseline HPV

Secondary Measures

  • The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment.
    • Time Frame: 6 months
    • The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment.
  • The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment.
    • Time Frame: 6 months
    • The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment.
  • The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment.
    • Time Frame: 6 months
    • The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment.
  • The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment.
    • Time Frame: 6 months
    • The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment.

Participating in This Clinical Trial

Inclusion Criteria

1. Biopsy-confirmed HSIL histology determined by a panel of 3 pathologists from a central laboratory in each region (China, US, and Europe);

2. Adequate colposcopy including:

1. visualization of entire cervical transformation zone including the squamocolumnar junction

2. visualization of entire lesion margin

3. Colposcopically visible lesion after biopsy, before treatment (Note: To ensure a colposcopically visible lesion after biopsy, the lesion should cover approximately 15% of the uterine cervix before biopsy)

4. Average sized uterine cervix suitable for application of the Cevira® device

5. Use of adequate birth control until completion of the 6 month assessment visit

6. Age 18 or older (Note: Patients aged 18-20 should not be actively recruited)

7. Signed written informed consent

Exclusion Criteria

1. Biopsy-confirmed HSIL (CIN3) histology with a total lesion area covering more than half of the uterine cervix area

2. Invasive cervical cancer

3. Adenocarcinoma in situ, or other glandular intraepithelial lesions

4. Lesion(s) extending to the cervical canal (as clinically indicated and whether to perform endocervical curettage [ECC] test at the discretion of the investigators)

5. Lesion(s) extending to the vaginal vault

6. Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infection as per colposcopy and clinical examination

7. Vaginal bleeding at time of treatment at the discretion of the investigator

8. Pregnancy

9. Nursing

10. Childbirth or miscarriage within six weeks of enrolment

11. Patients who previously received surgical treatment, have incomplete cervical structure and have recurrent HSIL; or patients who received other treatment after the confirmed diagnosis of HSIL

12. History of toxic shock syndrome

13. Known or suspected porphyria

14. Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)

15. Known allergy to silicone

16. Use of heart pacemaker

17. Participation in other therapeutic clinical trials using investigational agents either concurrently or within the last 30 days

18. Patients that in the investigator's opinion are not suitable for participation

19. Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Asieris MediTech (Hong Kong) Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jinghe Lang, MD,PhD, Principal Investigator, Peking Union Medical College Hospital
    • John Zhuang, PhD, Study Chair, Asieris MediTech (Hong Kong) Co., Ltd.
  • Overall Contact(s)
    • Mingming Zhang, MD, +8613816002336, mmzhang@asieris.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.